COX-2 inhibitors and cardiovascular risk

Muhammad R. Marwali; Jawahar L. Mehta

doi:10.1160/TH06-07-0385

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2006; 96(04): 401-406
DOI: 10.1160/TH06-07-0385

Theme Issue Article

Schattauer GmbH

COX-2 inhibitors and cardiovascular risk

Inferences based on biology and clinical studies

Muhammad R. Marwali

¹Cardiovascular Division, Department of Medicine, University of Arkansas for Medical Sciences, and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA

,

Jawahar L. Mehta

¹Cardiovascular Division, Department of Medicine, University of Arkansas for Medical Sciences, and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA

› Institutsangaben

Abstract

Summary

Even though non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used for a long time, the search continues for anti-inflammatory drugs with few side-effects. COX-2 inhibitors are currently most debated, because they have less gastrointestinal side effects but have been linked to increased cardiovascular morbidity and mortality, presumably related to thrombotic events. This has brought about the withdrawal of rofecoxib and other COX-2 inhibitors from the market. Although the results of several large studies with prospective, randomized design and meta-analysis of different trials have led to the demise of many popular COX-2 inhibitors, yet the conclusion seems to be rather simplistic. This review presents evidence from basic biology and clinical studies with the expectation that a balanced position, particularly in relation to increase in cardiovascular events, may be elucidated.

Keywords

Atherosclerosis - thrombosis - inflammation - hypercoagulability - coronary syndrome

Volltext

Referenzen

References
1 Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82.
2 Sugimoto Y, Segi E, Tsuboi K. et al. Female reproduction in mice lacking the prostaglandin F receptor. Roles of prostaglandin and oxytocin receptors in parturition. Adv Exp Med Biol 1998; 449: 317-21.
3 Ushikubi F, Segi E, Sugimoto Y. et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998; 395: 281-4.
4 Murata T, Ushikubi F, Matsuoka T. et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-82.
5 Lim H, Gupta RA, Ma WG. et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999; 13: 1561-74.
6 Hemler M, Lands WE. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 1976; 251: 5575-9.
7 Xie WL, Chipman JG, Robertson DL. et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
8 Fletcher BS, Kujubu DA, Perrin DM. et al. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992; 267: 4338-44.
9 O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60.
10 DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988; 85: 1412-6.
11 DeWitt DL, Smith WL. Cloning of sheep and mouse prostaglandin endoperoxide synthases. Methods Enzymol 1990; 187: 469-79.
12 Merlie JP, Fagan D, Mudd J. et al. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988; 263: 3550-3.
13 Funk CD, Funk LB, Kennedy ME. et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. Faseb J 1991; 05: 2304-12.
14 O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992; 89: 4888-92.
15 Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-8.
16 DuBois RN, Awad J, Morrow J. et al. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994; 93: 493-8.
17 Smith WL, Meade EA, DeWitt DL. Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann NY Acad Sci 1994; 744: 50-7.
18 Bazan NG. COX-2 as a multifunctional neuronal modulator. Nat Med 2001; 07: 414-5.
19 Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991; 1083: 1-17.
20 Langenbach R, Morham SG, Tiano HF. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92.
21 Morham SG, Langenbach R, Loftin CD. et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82.
22 Chandrasekharan NV, Dai H, Roos KL. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-31.
23 Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
24 FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42.
25 Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb J 2004; 18: 790-804.
26 Lian L, Wang Y, Draznin J. et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood 2005; 106: 110-7.
27 Tanaka N, Sato T, Fujita H. et al. Constitutive expression and involvement of cyclooxygenase-2 in human megakaryocytopoiesis. Arterioscler Thromb Vasc Biol 2004; 24: 607-12.
28 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
29 Weber AA, Zimmermann KC, Meyer-Kirchrath J. et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
30 Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977; 01: 18-20.
31 Topper JN, Cai J, Falb D. et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93: 10417-22.
32 Creminon C, Habib A, Maclouf J. et al. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays. Biochim Biophys Acta 1995; 1254: 341-8.
33 McAdam BF, Catella-Lawson F, Mardini IA. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology ofa selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
34 Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
35 Kobayashi T, Tahara Y, Matsumoto M. et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-94.
36 Mehta J. Platelets and prostaglandins in coronary artery disease. Rationale for use of platelet-suppressive drugs. J Am Med Assoc 1983; 249: 2818-23.
37 Mehta JL, Lawson D, Mehta P. et al. Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proc Natl Acad Sci USA 1988; 85: 4511-5.
38 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
39 Bombardier C, Laine L, Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8. 2 p following 1528.
40 Van Hecken A, Schwartz JI, Depre M. et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-20.
41 Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196-202.
42 Silverstein FE, Faich G, Goldstein JL. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000; 284: 1247-55.
43 Juni P, Rutjes AW, Dieppe PA. Are selective COX2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ 2002; 324: 1287-8.
44 Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-11.
45 Farkouh ME, Kirshner H, Harrington RA. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-84.
46 Kaufman DW, Kelly JP, Rosenberg L. et al. Are cyclooxygenase-2 inhibitors being taken only by those who need them?. Arch Intern Med 2005; 165: 1066-7.
47 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama 2001; 286: 954-9.
48 Graham DJ, Campen D, Hui R. et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
49 Solomon DH, Schneeweiss S, Glynn RJ. et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73.
50 Ray WA, Stein CM, Daugherty JR. et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3.
51 Juni P, Nartey L, Reichenbach S. et al. Risk of cardiovascular events and rofecoxib: cumulative metaanalysis. Lancet 2004; 364: 2021-9.
52 Solomon SD, McMurray JJ, Pfeffer MA. et al. Cardiovascular risk associated with celecoxib ina clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
53 Bresalier RS, Sandler RS, Quan H. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
54 Nussmeier NA, Whelton AA, Brown MT. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
55 Weber AA, Przytulski B, Schumacher M. et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002; 117: 424-6.
56 Censarek P, Freidel K, Udelhoven M. et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost 2004; 92: 925-8.
57 Yang HM, Kim HS, Park KW. et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004; 110: 301-8.
58 Cipollone F, Prontera C, Pini B. et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandinE synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104: 921-7.
59 Hermann M, Camici G, Fratton A. et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308-11.
60 Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588-95.
61 Bar FW, Meyer J, Michels R. et al. The effect of taprostene in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Saruplase Taprostene Acute Reocclusion Trial. Eur Heart J 1993; 14: 1118-26.
62 Mehta JL, Nichols WW. The potential role of thromboxane inhibitors in preventing myocardial ischaemic injury. Drugs 1990; 40: 657-65.
63 Schror K, Mehta P, Mehta JL. Cardiovascular risk of selective cyclooxygenase-2 inhibitors. J Cardiovasc Pharmacol Ther 2005; 10: 95-101.